TY - JOUR
T1 - Defining a standard set of patient-centered outcomes for men with localized prostate cancer
AU - Martin, Neil E.
AU - Massey, Laura
AU - Stowell, Caleb
AU - Bangma, Chris
AU - Briganti, Alberto
AU - Bill-Axelson, Anna
AU - Blute, Michael
AU - Catto, James
AU - Chen, Ronald C.
AU - D'Amico, Anthony V.
AU - Feick, Günter
AU - Fitzpatrick, John M.
AU - Frank, Steven J.
AU - Froehner, Michael
AU - Frydenberg, Mark
AU - Glaser, Adam
AU - Graefen, Markus
AU - Hamstra, Daniel
AU - Kibel, Adam
AU - Mendenhall, Nancy
AU - Moretti, Kim
AU - Ramon, Jacob
AU - Roos, Ian
AU - Sandler, Howard
AU - Sullivan, Francis J.
AU - Swanson, David
AU - Tewari, Ashutosh
AU - Vickers, Andrew
AU - Wiegel, Thomas
AU - Huland, Hartwig
PY - 2015/3/1
Y1 - 2015/3/1
N2 - Background Value-based health care has been proposed as a unifying force to drive improved outcomes and cost containment. Objective To develop a standard set of multidimensional patient-centered health outcomes for tracking, comparing, and improving localized prostate cancer (PCa) treatment value. Design, setting, and participants We convened an international working group of patients, registry experts, urologists, and radiation oncologists to review existing data and practices. Outcome measurements and statistical analysis The group defined a recommended standard set representing who should be tracked, what should be measured and at what time points, and what data are necessary to make meaningful comparisons. Using a modified Delphi method over a series of teleconferences, the group reached consensus for the Standard Set. Results and limitations We recommend that the Standard Set apply to men with newly diagnosed localized PCa treated with active surveillance, surgery, radiation, or other methods. The Standard Set includes acute toxicities occurring within 6 mo of treatment as well as patient-reported outcomes tracked regularly out to 10 yr. Patient-reported domains of urinary incontinence and irritation, bowel symptoms, sexual symptoms, and hormonal symptoms are included, and the recommended measurement tool is the Expanded Prostate Cancer Index Composite Short Form. Disease control outcomes include overall, cause-specific, metastasis-free, and biochemical relapse-free survival. Baseline clinical, pathologic, and comorbidity information is included to improve the interpretability of comparisons. Conclusions We have defined a simple, easily implemented set of outcomes that we believe should be measured in all men with localized PCa as a crucial first step in improving the value of care. Patient summary Measuring, reporting, and comparing identical outcomes across treatments and treatment centers will provide patients and providers with information to make informed treatment decisions. We defined a set of outcomes that we recommend being tracked for every man being treated for localized prostate cancer.
AB - Background Value-based health care has been proposed as a unifying force to drive improved outcomes and cost containment. Objective To develop a standard set of multidimensional patient-centered health outcomes for tracking, comparing, and improving localized prostate cancer (PCa) treatment value. Design, setting, and participants We convened an international working group of patients, registry experts, urologists, and radiation oncologists to review existing data and practices. Outcome measurements and statistical analysis The group defined a recommended standard set representing who should be tracked, what should be measured and at what time points, and what data are necessary to make meaningful comparisons. Using a modified Delphi method over a series of teleconferences, the group reached consensus for the Standard Set. Results and limitations We recommend that the Standard Set apply to men with newly diagnosed localized PCa treated with active surveillance, surgery, radiation, or other methods. The Standard Set includes acute toxicities occurring within 6 mo of treatment as well as patient-reported outcomes tracked regularly out to 10 yr. Patient-reported domains of urinary incontinence and irritation, bowel symptoms, sexual symptoms, and hormonal symptoms are included, and the recommended measurement tool is the Expanded Prostate Cancer Index Composite Short Form. Disease control outcomes include overall, cause-specific, metastasis-free, and biochemical relapse-free survival. Baseline clinical, pathologic, and comorbidity information is included to improve the interpretability of comparisons. Conclusions We have defined a simple, easily implemented set of outcomes that we believe should be measured in all men with localized PCa as a crucial first step in improving the value of care. Patient summary Measuring, reporting, and comparing identical outcomes across treatments and treatment centers will provide patients and providers with information to make informed treatment decisions. We defined a set of outcomes that we recommend being tracked for every man being treated for localized prostate cancer.
KW - Outcome measurement
KW - Patient-reported
KW - Prostate cancer
KW - Value
UR - http://www.scopus.com/inward/record.url?scp=84961291675&partnerID=8YFLogxK
U2 - 10.1016/j.eururo.2014.08.075
DO - 10.1016/j.eururo.2014.08.075
M3 - Article
C2 - 25234359
AN - SCOPUS:84961291675
SN - 0302-2838
VL - 67
SP - 460
EP - 467
JO - European Urology
JF - European Urology
IS - 3
ER -
